Daiichi To Market New Hib Vaccine For Children In December
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to begin marketing a new hemophilus influenza type B vaccine for children in Japan beginning Dec. 19. The ActHIB drug was developed by Sanofi Pasteur of France. Japan accounts for 25 of the estimated 400,000 deaths globally from the disease that usually is caused by meningitis and pneumonia. The disease usually strikes children between the ages of four and 18 months of age, and about 500 are affected by it in Japan each year. (Click here for more